ClinicalTrials.gg
CompletedNCT03125395Updated Aug 7, 2020Results posted

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

A Phase 3 interventional study of LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2020-08-07.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
13th of 20
57 · median 66
Started
2017
with 1 other
Phase 3
10 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 10 in phase 3, and was the 17th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for F508del.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects entering the Treatment Cohort must meet the following criteria:

  • Completed 24 weeks of LUM/IVA treatment and the Safety Follow-up Visit in Study VX15-809-115 Part B (Study 115B, NCT02797132)
  • Willing to remain on a stable CF medication regimen through the Safety Follow-up Visit

Subjects entering the Observational Cohort must meet 1 of the following criteria:

  • Completed 24 weeks of LUM/IVA treatment and the Safety Follow-up Visit in Study 115B, but do not want to enroll in the Treatment Cohort.
  • Received at least 4 weeks of LUM/IVA treatment and completed visits up to Week 24 and the Safety Follow-up Visit, if required, of Study 115B but are not taking LUM/IVA at the end of the Study 115B Treatment Period (i.e., Week 24) because of a drug interruption and either did not receive Vertex approval to enroll in the Treatment Cohort or do not want to enroll in the Treatment Cohort.
  • Permanently discontinued LUM/IVA in Study 115B after receiving at least 4 weeks of treatment and remained in the study from the time of treatment discontinuation through the Week 24 Visit and Safety Follow-up Visit, if required.

Exclusion criteria

Exclusion Criteria (Treatment Cohort Only):

  • Prematurely discontinued LUM/IVA treatment in Study 115B.
  • History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering LUM/IVA to the subject
  • History of drug intolerance or other serious reactions to LUM/IVA in Study 115B that would pose an additional risk to the subject in the opinion of investigator, and which should be discussed with the Vertex medical monitor.
  • Subjects with a history of allergy or to LUM/IVA.
  • Liver function test (LFT) abnormality meeting criteria for LUM/IVA treatment interruption at the completion of Study 115B, for which no convincing alternative etiology is identified.
  • value at the completion of Study 115B that would pose an additional risk to the subject in the opinion of investigator, and which should be discussed with the Vertex medical monitor
  • History of poor compliance with LUM/IVA and/or procedures in Study 115B as deemed by the investigator.
  • Participation in an drug trial (including studies investigating LUM and/or IVA) other than Study 115B.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    LUM/IVA

    LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.

    Drug: LUM/IVA

Interventions

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    Participants received LUM/IVA every q12h.

    Also known as: VX-809/VX-770, lumacaftor/ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 98

Secondary outcomes

  1. Absolute Change in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Parent Study 115B Baseline at Week 96

  2. Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: From Parent Study 115B Baseline at Week 96

  3. Absolute Change in BMI-for-age Z-score

    BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study 115B Baseline at Week 96

  4. Absolute Change in Weight

    Time frame: From Parent Study 115B Baseline at Week 96

  5. Absolute Change in Weight-for-age Z-score

    Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study 115B Baseline at Week 96

  6. Absolute Change From Baseline in Stature (Height)

    Time frame: From Parent Study 115B Baseline at Week 96

  7. Absolute Change in Stature-for-age Z-score

    Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study 115B Baseline at Week 96

  8. Time-to-first Pulmonary Exacerbation

    Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.

    Time frame: From Parent Study 115B Baseline through Week 96

  9. Number of Pulmonary Exacerbations (PEx)

    Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.

    Time frame: From Parent Study 115B Baseline through Week 96

  10. Number of Cystic Fibrosis (CF) Related Hospitalizations

    Time frame: From Parent Study 115B Baseline through Week 96

  11. Absolute Change in Fecal Elastase-1 (FE-1) Levels

    Time frame: From Parent Study 115B Baseline at Week 96

  12. Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels

    Time frame: From Parent Study 115B Baseline at Week 96

  13. Number of Participants With Microbiology Culture Status (Positive or Negative)

    Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.

    Time frame: Week 96

  14. Absolute Change in Lung Clearance Index (LCI) 2.5

    LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: From Parent Study 115B Baseline at Week 96

  15. Absolute Change in Lung Clearance Index (LCI) 5.0

    LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

    Time frame: From Parent Study 115B Baseline at Week 96

07

Results

Posted Aug 7, 2020

Participant flow

This study was planned to have 2 cohorts: Treatment Cohort and Observational Cohort. Only the Treatment Cohort is presented in results as there were no participants enrolled in the Observational Cohort.

Participant flow — Overall Study
MilestoneLUM/IVA
Started57
Study 115b fas60
Study 116 fas57
Study 116 lci substudy set31
Completed47
Not completed10
Withdrew: Adverse event2
Withdrew: Withdrawal of consent (not due to ae)1
Withdrew: Physician decision2
Withdrew: Commercial drug is available5

Outcome measures

PrimarySafety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 98
Reported as:
Number · participants
Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsLUM/IVA
Participants with AEs56
Participants with SAEs15
SecondaryAbsolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride
millimole per liter (mmol/L)LUM/IVA
Absolute Change in Sweat Chloride-29.6 ± 12.7
SecondaryAbsolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · kg/m^2
Absolute Change in Body Mass Index (BMI)
kg/m^2LUM/IVA
Absolute Change in Body Mass Index (BMI)0.30 ± 1.21
SecondaryAbsolute Change in BMI-for-age Z-score

BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · z-score
Absolute Change in BMI-for-age Z-score
z-scoreLUM/IVA
Absolute Change in BMI-for-age Z-score0.27 ± 0.73
SecondaryAbsolute Change in Weight
Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · kg
Absolute Change in Weight
kgLUM/IVA
Absolute Change in Weight6.0 ± 2.0
SecondaryAbsolute Change in Weight-for-age Z-score

Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · z-score
Absolute Change in Weight-for-age Z-score
z-scoreLUM/IVA
Absolute Change in Weight-for-age Z-score0.23 ± 0.56
SecondaryAbsolute Change From Baseline in Stature (Height)
Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · centimeter
Absolute Change From Baseline in Stature (Height)
centimeterLUM/IVA
Absolute Change From Baseline in Stature (Height)16.1 ± 2.3
SecondaryAbsolute Change in Stature-for-age Z-score

Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · z-score
Absolute Change in Stature-for-age Z-score
z-scoreLUM/IVA
Absolute Change in Stature-for-age Z-score0.07 ± 0.39
SecondaryTime-to-first Pulmonary Exacerbation

Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.

Time frame:
From Parent Study 115B Baseline through Week 96
Reported as:
Median · days
Time-to-first Pulmonary Exacerbation
daysLUM/IVA
Time-to-first Pulmonary Exacerbation600.0 (98.0 to NA)
SecondaryNumber of Pulmonary Exacerbations (PEx)

Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.

Time frame:
From Parent Study 115B Baseline through Week 96
Reported as:
Number · pulmonary exacerbation events
Number of Pulmonary Exacerbations (PEx)
pulmonary exacerbation eventsLUM/IVA
Number of Pulmonary Exacerbations (PEx)82
SecondaryNumber of Cystic Fibrosis (CF) Related Hospitalizations
Time frame:
From Parent Study 115B Baseline through Week 96
Reported as:
Number · hospitalizations
Number of Cystic Fibrosis (CF) Related Hospitalizations
hospitalizationsLUM/IVA
Number of Cystic Fibrosis (CF) Related Hospitalizations28
SecondaryAbsolute Change in Fecal Elastase-1 (FE-1) Levels
Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · microgram per gram (mcg/g)
Absolute Change in Fecal Elastase-1 (FE-1) Levels
microgram per gram (mcg/g)LUM/IVA
Absolute Change in Fecal Elastase-1 (FE-1) Levels132.6 ± 174.2
SecondaryAbsolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels
Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · nanogram per milliliter (ng/mL)
Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels
nanogram per milliliter (ng/mL)LUM/IVA
Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels-108.5 ± 306.6
SecondaryNumber of Participants With Microbiology Culture Status (Positive or Negative)

Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Microbiology Culture Status (Positive or Negative)
participantsLUM/IVA
Burkholderia (Positive)0
Burkholderia (Negative)46
MRSA (Positive)4
MRSA (Negative)42
MSSA (Positive)15
MSSA (Negative)31
P. Aeruginosa Mucoid (Positive)0
P. Aeruginosa Mucoid (Negative)46
P. Aeruginosa Non-Mucoid (Positive)1
P. Aeruginosa Non-Mucoid (Negative)45
P. Aeruginosa Small Colony Variant (Positive)0
P. Aeruginosa Small Colony Variant (Negative)46
Stenotrophomonas Maltophilia (Positive)2
Stenotrophomonas Maltophilia (Negative)44
SecondaryAbsolute Change in Lung Clearance Index (LCI) 2.5

LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · lung clearance index
Absolute Change in Lung Clearance Index (LCI) 2.5
lung clearance indexLUM/IVA
Absolute Change in Lung Clearance Index (LCI) 2.5-0.20 ± 1.55
SecondaryAbsolute Change in Lung Clearance Index (LCI) 5.0

LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

Time frame:
From Parent Study 115B Baseline at Week 96
Reported as:
Mean · lung clearance index
Absolute Change in Lung Clearance Index (LCI) 5.0
lung clearance indexLUM/IVA
Absolute Change in Lung Clearance Index (LCI) 5.00.11 ± 0.65

Adverse events

Collected over Day 1 up to Week 98. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM/IVA0/57 (0%)15/57 (26.3%)55/57 (96.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventLUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations6/57
PneumoniaInfections and infestations2/57
ConstipationGastrointestinal disorders1/57
HaematemesisGastrointestinal disorders1/57
PancreatitisGastrointestinal disorders1/57
AppendicitisInfections and infestations1/57
Chronic sinusitisInfections and infestations1/57
Gastritis viralInfections and infestations1/57
Gastroenteritis adenovirusInfections and infestations1/57
Gastroenteritis viralInfections and infestations1/57
Most frequent other events
Showing 10 of 41
Most frequent other events
EventLUM/IVA
CoughRespiratory, thoracic and mediastinal disorders47/57
Nasal congestionRespiratory, thoracic and mediastinal disorders25/57
PyrexiaGeneral disorders23/57
RhinorrhoeaRespiratory, thoracic and mediastinal disorders18/57
VomitingGastrointestinal disorders17/57
Upper respiratory tract infectionInfections and infestations13/57
Ear infectionInfections and infestations12/57
SinusitisInfections and infestations12/57
Staphylococcus test positiveInvestigations12/57
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations10/57

Baseline characteristics

Age, Continuous
Age, Continuous(months)LUM/IVA
Mean43.2 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)LUM/IVA
Female28
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LUM/IVA
Hispanic or Latino3
Not Hispanic or Latino54
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LUM/IVA
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White56
More than one race0
Unknown or Not Reported1
08

Study locations

20 sites
  • Stanford University
    Palo Alto, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minn
    Minneapolis, Minnesota 55404, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • The Lung & Cystic Fibrosis Center at Women's & Children's Hospital of Buffalo
    Buffalo, New York 14222, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland Medical Center/Rainbow Babies and Children's Hospital
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • British Columbia's Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Quebec H4A 3J1, Canada
09

References and documents

Publications

  • Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med. 2021 Sep;9(9):977-988. doi: 10.1016/S2213-2600(21)00069-2. Epub 2021 May 6. PubMed 33965000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2019, 26 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2017
First posted
Apr 24, 2017
StartActual
May 12, 2017
Primary completionActual
Jul 17, 2019
CompletionActual
Jul 17, 2019
Results first posted
Aug 7, 2020
Last update
Aug 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03125395
Responsible party
Sponsor
First posted
Apr 24, 2017
Start date
May 12, 2017
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019
Results posted
Aug 7, 2020
Last update
Aug 7, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion